header logo image


Page 33«..1020..32333435..40..»

Archive for the ‘Personalized Medicine’ Category

Conference to Focus on AI in Arkansas – Arkansas Business Online

Monday, November 18th, 2019

We were unable to send the article.

The sixth annual Arkansas Bioinformatics Consortium conference is set for Feb. 10-11 at the Wyndham Riverfront in North Little Rock. Its theme is Artificial Intelligence in Arkansas.

AR-BIC is an annual event, but its meant to be a collaborative community of research scientists and practitioners in this field of bioinformatics, said Jeremy Harper, director of communications for the Arkansas Research Alliance.

ARA, headquartered in Conway, is the lead organizer of the conference. The Food & Drug Administrations National Center for Toxicological Research in Jefferson County is a major sponsor.

Harper said conference registration is free and complementary lodging is available, thanks to a $15,000 grant from the FDA and sponsorships that cover what remains of its $40,000-$50,000 budget.

The conference will be held from 1-7:30 p.m. Feb. 10 and from 8:30 a.m.-4:30 p.m. Feb. 11.

AR-BIC was born out of a realization by the NCTRs Division of Bioinformatics & Biostatistics and others that we have a real developing, emerging competency in bioinformatics here in the state and it needed to be nurtured, Harper said. The objectives of AR-BIC, he said, are to:

The first conference attracted 90 attendees, and attendance has been growing since then, Harper said. More than 200 attended the 2019 conference.

The AR-BIC governing board oversees the conference. The board includes representatives from Arkansas State University, the University of Arkansas, the University of Arkansas at Little Rock, the University of Arkansas for Medical Sciences, the University of Arkansas at Pine Bluff, the NCTR and ARA. ARA President and CEO Jerry Adams chairs it. Entities represented on the board provide most of the conferences speakers.

Highlights of the 2020 conference include a new panel composed of ARA Academy scholars and fellows and a theme that is on point, Harper said.

This [upcoming] year is on AI, and theres just been an explosion of growth around AI, he said. The computational requirements of personalized medicine alone, not to mention things like driverless cars and all that, make it a pretty strategic theme.

Harper also said the FDA, a major sponsor, will need AI to do its job, which is to protect human health.

In addition, the topic is timely, he said, because ARA fellow Xiuzhen Huang of A-State recently founded the Arkansas AI-Campus. It is a virtual statewide interactive training program seven institutions are participating in. The program allows researchers to work with global and national experts in machine learning, artificial intelligence and deep learning. Deep learning is the practice of imitating the workings of the human brain in processing data and creating patterns for use in decision-making.

View post:
Conference to Focus on AI in Arkansas - Arkansas Business Online

Read More...

Genentech to Present New and Updated Data for Seven Approved and Investigational Medicines Across Multiple Types of Breast Cancer at the 2019 San…

Monday, November 18th, 2019

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Nov 18, 2019--

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that results from a number of studies across its growing breast cancer portfolio will be presented at the San Antonio Breast Cancer Symposium (SABCS) on December 10-14, 2019. These data include new results in HER2-positive breast cancer and studies of new molecules in hormone receptor-positive (HR-positive) breast cancer.

For the past three decades, we have remained dedicated to improving outcomes for people with breast cancer, said Levi Garraway, M.D., Ph.D., chief medical officer and head of Global Product Development. This sustained commitment is exemplified by new data for our approved and investigational medicines across the spectrum of breast cancer being presented at SABCS this year.

Key presentations

New data will be presented from a second interim overall survival (OS) analysis of the Phase III APHINITY trial evaluating Perjeta (pertuzumab) and Herceptin (trastuzumab) plus chemotherapy (the Perjeta-based regimen), compared to Herceptin and chemotherapy, as an adjuvant treatment for HER2-positive early breast cancer (eBC). This latest interim OS analysis also includes updated descriptive invasive disease-free survival and cardiac safety data.

Genentech will also present data from the primary analysis of the Phase III FeDeriCa study which evaluated a new investigational fixed-dose combination (FDC) of Perjeta and Herceptin administered as a single subcutaneous formulation in combination with intravenous chemotherapy. The FDC is administered under the skin in just minutes, significantly reducing the time spent receiving treatment and providing people with HER2-positive breast cancer a potential new treatment option for faster delivery of the Perjeta-based regimen.

Data will also be presented from studies in HR-positive breast cancer, including findings from early studies investigating Genentechs pipeline molecules GDC-9545, a selective estrogen receptor degrader, and GDC-0077, a mutant selective PI3K inhibitor.

Overview of Genentech studies to be presented at SABCS 2019

Medicine(s)

Abstract title

Abstract number

(date, time, location of presentation)

HER2-positive breast cancer

Perjeta and Herceptin

Interim OS analysis of APHINITY (BIG 4-11): a randomized multicenter, double-blind, placebo-controlled trial comparing chemotherapy plus trastuzumab plus pertuzumab versus chemotherapy plus trastuzumab plus placebo as adjuvant therapy in patients with operable HER2-positive eBC

Abstract GS1-04

(Oral)

Wednesday, December 119:30 9:45 AM CST

Hall 3

Perjeta and Herceptin

Subcutaneous trastuzumab and hyaluronidase-oysk with intravenous pertuzumab and docetaxel in HER2-positive advanced breast cancer: final analysis of the Phase IIIb, multicenter, open-label, single-arm MetaPHER study

Abstract P1-18-05

(Poster)

Wednesday, December 115:00 7:00 PM CST

Hall 1

Perjeta and Herceptin

Risk of recurrence and death in patients with early HER2-positive breast cancer who achieve a pathological complete response (pCR) after different types of HER2-targeted therapy: a retrospective exploratory analysis

Abstract P1-18-01

(Poster)

Wednesday, December 115:00 7:00 PM CST

Hall 1

Perjeta and Herceptin

Use of pertuzumab in combination with taxanes for HER2-positive metastatic breast cancer (MBC): analysis of United States electronic health records

Abstract P1-18-14

(Poster)

Wednesday, December 115:00 7:00 PM CST

Hall 1

Kadcyla (ado-trastuzumab emtansine)

Cardiac events in patients with HER2-positive MBC who have low left ventricular ejection fraction prior to initiating treatment with ado-trastuzumab emtansine: a retrospective cohort study using electronic health record data

Abstract P1-18-11

(Poster)

Wednesday, December 115:00 7:00 PM CST

Hall 1

Tecentriq (atezolizumab), Kadcyla, Perjeta and Herceptin

Atezolizumab in combination with ado-trastuzumab emtansine or with trastuzumab and pertuzumab in patients with HER2-positive breast cancer and atezolizumab with doxorubicin and cyclophosphamide in HER2-negative breast cancer: safety and biomarker outcomes from a multi-cohort Phase Ib study

Abstract PD1-05

(Poster discussion)

Wednesday, December 115:00 7:00 PM CST

Hemisfair Ballroom

Perjeta and Herceptin

Subcutaneous administration of the fixed-dose combination of trastuzumab and pertuzumab in combination with chemotherapy in HER2-positive eBC: primary analysis of the Phase III, multicenter, randomized, open-label, two-arm FeDeriCa study

Abstract PD4-07

(Poster discussion)

Thursday, December 12

7:00 9:00 AM CST

Stars at Night Ballroom 1&2

Kadcyla and Perjeta

Association of immune gene expression with outcome in the MARIANNE Phase III clinical trial in HER2-positive MBC

Abstract PD5-11

(Poster discussion)

Thursday, December 12

7:00 9:00 AM CST

Stars at Night Ballroom 3&4

Kadcyla and Herceptin

Adjuvant ado-trastuzumab emtansine versus trastuzumab in patients with residual invasive disease after neoadjuvant therapy for HER2-positive breast cancer: KATHERINE subgroup analysis

Abstract P3-14-01

(Poster)

Thursday, December 12

5:00 7:00 PM CST

Hall 1

Herceptin

Palbociclib in combination with trastuzumab and endocrine therapy versus treatment of physician's choice in metastatic HER2-positive and HR-positive breast cancer with PAM50 luminal intrinsic subtype (SOLTI-1303 PATRICIA II): a multi-center, randomized, open-label, Phase II trial

Abstract OT2-02-06

(Poster)

Thursday, December 12

5:00 7:00 PM CST

Hall 1

Kadcyla and Herceptin

Cost-effectiveness of ado-trastuzumab emtansine versus trastuzumab for the adjuvant treatment of patients with residual invasive HER2-positive eBC in the United States

Abstract P6-13-01

(Poster)

Saturday, December 14

7:00 9:00 AM CST

Hall 1

Hormone receptor-positive

GDC-0077

A first-in-human Phase Ia dose escalation study of GDC-0077, a p110a-selective and mutant-degrading PI3K inhibitor, in patients with PIK3CA-mutant solid tumors

Abstract OT1-08-04

(Poster)

Wednesday, December 11

5:00 7:00 PM CST

Hall 1

GDC-0077

A Phase Ib dose escalation study evaluating the mutant selective PI3K-alpha inhibitor GDC-0077 in combination with letrozole with and without palbociclib in patients with PIK3CA-mutant HR-positive, HER2-negative breast cancer

Abstract P1-19-46

(Poster)

Wednesday, December 11

5:00 7:00 PM CST

Hall 1

GDC-9545

See the original post:
Genentech to Present New and Updated Data for Seven Approved and Investigational Medicines Across Multiple Types of Breast Cancer at the 2019 San...

Read More...

Australias 3D Printing Medical Conference: Focusing on Technology and Teamwork to Advance the Field – 3DPrint.com

Monday, November 18th, 2019

Why has nobody really 3D printed a heart yet? Will animals also benefit from 3D printing in the veterinary field? How to start a 3D printing lab in a public hospital? And who is Gary? These are just a few of the proposals answered at the latest and fifth edition of the 3D Med Australia Conference, which concluded last Saturday after three days of workshops, lab tours, and lectures at the AAMI Park, a huge Stadium in Melbourne. The event highlighted 3D printing applications in various health areas like presurgical planning in adult and pediatric fields, bioprinting, medical device design, prosthetic and implantable device design, education of trainees and medical students, as well as patient experience, and even 3D printing to support longevity of equipment for helicopter retrieval (from blood warmers to vial containment).It is the largest 3D technologies in medicine conference in Australasia, convened by Jason Chuen, Associate Professor at The University of Melbourne and Director of Vascular Surgery at Austin Health, in Melbourne, and Jasamine Coles-Black, doctor and vascular researcher at the Department of Vascular Surgery at Austin Health and Austin 3D Medical Printing Laboratory (Austin 3D Med Lab). Apart from featuring frontier health innovation in 3D printing, it was attended by most major labs and scientists in this space.

The highly awaited experience showcased The University of Melbournes experience in this space, as a recognized hotspot of medical device innovation. The multidisciplinary nature of frontier technologies in health meant the work presented is a result of the collaboration between doctors, engineers, veterinarians, cell biologists, industrial designers, lawyers, and policymakers.

3D technologies, including 3D printing and augmented reality, are set to radically transform the way we teach, train, plan, rehearse, and perform surgery; and Australia is lining up to be one of the leaders in the field, said Chuen. We are proud to support this by bringing together all of these great minds: from what I can see, Australia, and Melbourne, in particular, will be a major hub of medical technology development, and 3D related technologies will be a key part of this.

Atandrila Das, General Surgeon at Northern Health, Melbourne, presented a world-first case combining 3D visualization with robotic cancer surgery, which was a result of a collaboration between Austin Health and the Peter MacCallum Cancer Centers Department of Surgery doctoral students and surgeons. In addition, Claudia di Bella, Orthopaedic Surgeon, and researcher at Biofab3D in St Vincents Hospitalat The University of Melbourne exhibited her robotics and tissue engineering work.

Additionally, ethics and regulation were a big part of the event, with attendees getting updates from Australian governing bodies like the Therapeutic Goods Administration (TGA), the Department of Health and Human Services (DHHS), and Medical Device Innovation. The TGAs John Skerritt provided leading researchers with an update on the current changes to custom medical device and implant regulations coming in late November. Some of the proposals for change include a medical device production system framework to allow healthcare providers to produce lower risk personalized devices without manufacturing certification and regulation of medical devices with a human origin component as medical devices with a biological component rather than biologicals.

What is wrong with this image? OConnell explains why nobody has really 3D printed a heart yet (Image Credit: Cathal OConnell)

During the talk Dont Print Your Heart Out, facility manager at BioFab3D, Cathal OConnell, dissected the hype from reality and explained why nobody has really 3D printed a heart yet, suggesting it is dangerous to provoke so much buildup in platform technologies and how clinicians, scientists, and reporters need to be careful when delivering their message on medical technologies.

In the original printed heart scientific paper, Israeli scientists describe [] the main focus was to print a square patch of heart cells and blood vessels using a personalized bioink. As a final flourish, the team also printed the cells into a thumbnail-sized, heart shape. The text of the original paper clearly states the printed heart-shaped structure is not a real heart and lacks most of the features required to make a heart work. This is impressive work the cardiac patches may indeed turn out to be an important development in the field. Im more worried about media reports giving the impression that our field of research is far more advanced than it is, said OConnell.

Elizabeth Sigston at the Women in 3D Med Event (Image Credit: Austin 3D Med Lab)

While Blake Cochran, from the University of New South Wales (UNSW), Sydney, introduced Gary, a 3D printed radiologically realistic skull, and Stewart Ryan, from The University of Melbourne Universitys vet school, explored the importance of 3D printing for the training of veterinary surgeons for all creatures great and small, and Ryan should know, he has even performed surgery for a 14-year old tiger at the Melbourne Zoo to remove a cancerous tumor.

As part of the event, the inaugural Women in 3D Technologies networking drinks were held in partnership with the Commonwealth Scientific and Industrial Research Organisation (CSIRO), with Elizabeth Sigston (a leading head and neck cancer surgeon) giving the keynote speech. The conference proved that there is a strong representation of women in STEMM careers across Medicine, Dentistry and Health Sciences (MDHS) in Melbourne.

3D technologies are the natural next steppingstone in the era of personalised medicine, said Coles-Black. Australian doctors, engineers and other researchers need to come together in order to make the most of this new frontier in medicine. Our conference provides a collegiate environment for much-needed multidisciplinary collaboration.

Jason Chuen, Elizabeth Sigston, Frank McGuire, and Jasamine Coles-Black at the 3D Med Conference (Image Credit: Austin 3D Med Lab)

Coles-Black also explained that this conference seeks to bring together experts to solve the often-quoted barriers to the adoption of 3D printing technologies in healthcare settings, such as the lack of technical and regulatory knowledge, perceived costs, and lack of expertise in implementation.

A tour of RMITs Additive Manufacturing Precinct (Image Credit: Austin 3D Med Lab)

In addition, the conference featured a tour of the new MDHS SBS Digital Learning Hub. Other University of Melbourne labs featured through hands-on tours included the Melbourne School of Designs NExT Lab and BioFab3d, Austin 3D Med Lab, and the Australian Research Council Training Centre for Medical Implant Technologies (ARC-CMIT)which launched on November 8. In addition, there was a significant focus on industry, startup and commercialization, and medical device development with representatives from the Medical Device Partnering Program, Stratasys, HP, Evok3D, Kyocera, Leapfrog, Gore, Global3D and Materialise.

Clinicians and engineers need to work together to develop this technology and find ways to implement it effectively and safely. Collaboration is key in this industry, claimed Chuen.

During the occasion, there was a lot of hype about the clinical uses of augmented and virtual reality in presurgical planning, medical student education, forensics, trauma simulation, and to improve hospital systems.

At the Anatomical 3D Segmentation Workshop, in collaboration with Evok3D, an HP 3D Partner in Australia, guests learned more about the end-to-end workflows for the production of 3D printed color anatomical models, which can be used to improve pre-surgical planning, patient consultation, and support medical education. Medical 3D technology for patient care is getting more and more accessible, every day, providing patients personalized treatment based on their scans as point-of-care 3D printing enables manufacturing directly on location.

Promotional booths were a big part of the event, with visitors looking into how Materialise solutions can provide personalized treatment to patients and guidance on setting up a 3D point-of-care facility at hospitals. And Stratasys even chose the 3D Med Conference to launch its J750 Digital Anatomy Printer in the Australasia region.

The last day of the event kicked off with Mia Woodruff, Professor of Biomedical Engineering at Queensland University of Technology (QUT), and Gordon Wallace, a distinguished professor at theUniversity of Wollongong (UOW), talking about the future of bioprinting. Woodruff shared challenges and motivations to translate biofabrication in the hospital of the future, and along with Wallace announced the Biofabrication 2020 event: Biofab by the Beach, set for September 27 through 30, in 2020, proving its all about teamwork, something Wallace was keen on emphasizing during his panel, claiming cross-disciplinary collaboration is key and Australia leads the way as Australians are collaborative by nature. Finally, rounding up the event was Peter Lee, Director of the ARC CMIT, focusing on building the multidisciplinary networks needed to train the new generation of implant engineers. Thats what it was all about at the 3D Med Conference, looking into the future for biotechnology and medical applications that will pave the way for future research and adoption of 3D printing technology.

The entrance to the 3D Med Conference (Image Credit: Austin 3D Med Lab)

See the original post:
Australias 3D Printing Medical Conference: Focusing on Technology and Teamwork to Advance the Field - 3DPrint.com

Read More...

David Crais of CMG Carealytics Invited to NASA Cross Industry Innovation Summit – Benzinga

Monday, November 18th, 2019

New Orleans, LA, November 18, 2019 --(PR.com)-- David Crais, CEO of CMG Carealytics, was invited to the 4th Cross-Industry Innovation Summit held at Johnson Space Center in Houston, Texas last week. An exclusive group of Chief Innovation Officers from NASA, the US Navy, Army, Columbia University Business School, Barnard College, Amazon, Google, Dow Jones, and other global organizations.

Held over three days last week at Johnson Space Center, the Cross Industry Innovation Summit is a deep dive into innovation theory and practice from venture capital, startups, and technology transfer to corporate innovation labs and research and development programs. Exploring the discovery and investigative process with manufacturing, development, and commercialization and adoption of emerging technologies, new ideas, and new program development, these business, social, and government leaders work hands on to share ideas and cultural outlook and framework to bring about advances to their domains and constituencies . This is the fourth year of the program and the fourth year David Crais was asked to participate.

CMG Carealytics, a product management and development firm specializing in scientific, medical, and complex systems and industries, is known as a leader in the innovation and commercialization field. Working with incubators, accelerators, R&D teams, tech parks, venture capital firms, and expert networks, CMG Carealytics founded and led by David Crais continues to spearhead new innovation methods and practices in quality engineering, agile, scrum, lean, buisness analysis, product management, and other sociotechnical methods and in technologies from biotech, regenerative medicine, medical device, digital medicine, personalized medicine, printed electronics, imaging, thermography, and other technologies.

Crais has been engaged in innovation theory since his university education in scientific history and social change up to his development of medical technologies and taking them to market as publicly traded companies, private placements, new product launches, non-profits, and with economic development initiatives.

His participation in the Cross-Industry Summit with NASA is in addition to his work in serving on the Master Plan Task Force with Stennis Space Center in Mississippi, as a board member on the LSU Stephenson Entrepreneurship Institute, an advisor to Nevada State College Entrepreneurship Program, UC Irvine Medical Technology Commercialization Program, and with organizations like the Urban Land Institute, Angel Capital Association, Association for Corporate Growth, and other roles.

Contact Information:CMG CarealtyicsDavid Crais773-398-4143Contact via Emailcraisgroup.comghartman1@hotmail.com

Read the full story here: https://www.pr.com/press-release/799655

Press Release Distributed by PR.com

Excerpt from:
David Crais of CMG Carealytics Invited to NASA Cross Industry Innovation Summit - Benzinga

Read More...

The right tech can help give doctors back time with patients: AMA CEO – American Medical Association

Monday, November 18th, 2019

Augmentedintelligence(AI) iscertainto bea key player in revolutionizinghealthcare for the next generation of physiciansand patients. Butwhat about actual intelligence, the kind producedby human brains?

It, too, will be instrumental, AMA Executive Vice President and CEO James L. Madara, MD, noted in his address to delegates at the opening session of the 2019 AMA Interim Meeting in San Diego.

To make his point, Dr. Madara cited a recent anecdote from tech entrepreneur and investor Elon Musk, the founder of electric automaker Tesla. When the car company struggled to keep up with the production schedule on the Tesla Model 3, Musk came to the conclusion that the problem was an overreliance on AI.

Now, this story captures two principles, Dr. Madara said. The first is that to produce something of value, one needs to perform a complicated series of discrete actions in a highly coordinated way. The second, the best outcomes may require powerful technologies optimally mixed with distinctively human capabilities.

These principles, Dr. Madara said, are reflected in the AMAs work on evaluating and acting on chronic disease. Among the interventions the CEO cited:

Policies and reports adopted in the AMA House of Delegates over the past half decade that detail significant health burdens of diabetes and hypertension.

When complete, our collective work will have ushered in more accurate and organized measures of blood pressure, better insights into how to better control blood pressure, no paperwork, and added revenue to physicians for evaluating and acting on hypertension, this the No. 1 killer in our society, Dr. Madara said.

This blood pressure story is but one example of how were harnessing the power of the AMAexpertise across many units cross-leveraging many strengthsand doing so in a systematic and coordinated fashion.

In providing additional examples of what can be accomplished with the collective power of the AMAs membership, Dr. Madara again called out the AMA Ed Hub.

Launched in May, the platform hosts a broad spectrum continuing medical education (CME) content. Some of that material is sourced from the American College of Radiology, with other medical specialties, expressing interest in a similar arrangement.

Ed Hub also began electronically syncing CME offerings with specialty boards, such as the American Board of Internal Medicine, and has the capability to connect with state licensing processes. That atuomatic tracking is now being piloted in North Carolina, Tennessee and Maine, and other states will follow.

Taking the concept of innovation a step further, Ed Hub is working with the AMAs tech incubator, Health2047 Inc., to potentially develop AI features that could personalize a physicians CME options.

Imagine a future where your CME choices are crafted as a bespoke menu, customized to what you actually see in your practice, and where the hassles of filling out forms for credentialing and licensing disappear. Thats the pathway were building, Dr. Madara said.

Technology advancements, Dr. Madara said, are only a tool to provide better carenot a way to replace physicians, nurses and other dedicated health professionals.

Dr. Madara illustrated that point through the changes in the process of counting blood cell types. As a medical student, he counted them using a clicker. Over time, that process changed from a clicker to a coulter counter to a flow cytometers to a cell separator.

Each time, the old task was replaced by a more interesting new taskallowing advances in diagnosis and therapy, he said.When it comes to powerful new tools and machines, its important to remember these replace tasks, not jobs. Its our role to imagine new frontiersnew tasksthat further advance our fields with yesterdays brute labor now taken up by the machines.

In the end, more time with patients for physicians because of these advancements will change the job, in a way that makes it more fulfilling.

Count me among those excited about the future of medicine, and the powerful new tools that will define the new era of personalized patient care, and also personalized physician education driven by the AMA Ed Hub, he said. Im confident in the physicians ability to always reach the next future statein part because physicians will always have the AMA as their powerful ally in patient care, and because we will forever strive to promote the art and science of medicine and the betterment of public health.

Follow this link:
The right tech can help give doctors back time with patients: AMA CEO - American Medical Association

Read More...

Tremendous Opportunities in Artificial Intelligence in Medicine Market 2019 Development Trend and Forecast with Top Players | Welltok, Inc., Intel…

Monday, November 18th, 2019

According to the report, the global artificial intelligence (AI) in medicine market generated $719 million in 2017 and is expected to garner $18.12 billion by 2026, growing at a CAGR of +49.6% during the forecast period.

The growth of global artificial intelligence (AI) in the medical market is driven by a surge in AI functioning due to increased processing capacity, the need to compensate for the lack of skilled professionals in health care, and increased awareness of the importance of personalized medicine. . But the limitations of AI in decision making and the slow acceptance of AI by healthcare professionals hinder market growth. Nevertheless, as the adoption of AI technology increases in developing countries, it will soon be a lucrative opportunity for players in emerging markets.

For Sample copy of this Report:

https://healthcareintelligencemarkets.com/request_sample.php?id=135746

Companies Profiled in this Report Includes:Welltok, Inc., Intel Corporation, Nvidia Corporation, Google Inc., IBM Corporation, Microsoft Corporation, General Vision, Inc., Enlitic, Inc., BioXcel Corporation, and Berg Health.

Increased investment in pharmaceutical and biotechnology companies for Artificial Intelligence in Medicine and the growing number of patients requiring organ transplantation are key factors supporting the growth of the Artificial Intelligence in Medicine market worldwide. In addition, animal research and testing bans are expected to drive Artificial Intelligence in Medicine across a variety of applications. However, high initial investment can inhibit market growth. In addition, the development of Artificial Intelligence in Medicine for making customized cosmetics will provide growth opportunities for the market in the near future.

The key questions answered in the report:

The global Artificial Intelligence in Medicine market is classified as technology, application and end user. By technology, the market is classified as extracellular matrix, bioreactor, gel, scaffold free platform and microchip. Depending on the application, the market is subdivided into research, drug discovery, tissue engineering, clinical applications and stem cell biology. End users are also divided into laboratories and laboratories, biotechnology and biopharmaceutical industries, and hospitals and diagnostic centers.

Access Complete Report @:

https://healthcareintelligencemarkets.com/enquiry_before_buying.php?id=135746

A viable analysis of the Artificial Intelligence in Medicine market has also been provided in this statistical report in which the outlines of the key market players have been studied thoroughly to regulate the markets hierarchy. As per the research report, the market is greatly uneven and competitive due to the number of participants. This research study is intended to give a clear picture of the Artificial Intelligence in Medicine market to the readers in order to benefit them in gaining a better understanding of this market.

Globally, Europe, Asia-Pacific, North America, Middle East & Africa and Latin America are the geographical regions of the market for agricultural impetus. This Artificial Intelligence in Medicine market report also elaborates on the drivers, restraints and opportunities of the market in the present and forthcoming years.

Objectives of this research report:

Get Discount on This Premium Research now @:

https://healthcareintelligencemarkets.com/ask_for_discount.php?id=135746

About Us:

At HealthCare Intelligence Markets

Contact Us:

Address: 90, State Office Center,

90, State Street Suite 700,

Albany, NY 12207

Email: sales@healthcareintelligencemarkets.com

Web: http://www.healthcareintelligencemarkets.com

Phone: +1 (888) 616-2766

Read more here:
Tremendous Opportunities in Artificial Intelligence in Medicine Market 2019 Development Trend and Forecast with Top Players | Welltok, Inc., Intel...

Read More...

Cardiac Resynchronization Therapy Helps Cancer Survivors With Heart Failure – DocWire News

Monday, November 18th, 2019

Cardiac resynchronization therapy (CRT) improved left ventricular ejection fraction(LVEF) after six months in cancer survivors with chemotherapy-induced cardiomyopathy, according to a study published in JAMA.

The uncontrolled, prospective, cohort Multicenter Automatic Defibrillator Implantation TrialChemotherapy-Induced Cardiomyopathy study was conducted between November 21, 2014, and June 21, 2018, at 12 U.S. tertiary centers with cardio-oncology programs.

A total of 30 patients (mean age, 64 years) were implanted with CRT due to reduced LVEF (defined as 35%), New York Heart Association class II-IV heart failure symptoms, and wide QRS complex, with established chemotherapy-induced cardiomyopathy. Among this cohort, 73% had a history of breast cancer and 20% had a history of lymphoma or leukemia. Twenty-six patients were evaluable for primary endpoint data (change in LVEF from baseline to six months after CRT initiation).

Patients had non-ischemic cardiomyopathy with left bundle branch block, a median LVEF of 29%, and a mean QRS duration of 152 ms.

Patients with CRT experienced a statistically significant improvement in mean LVEF at six months, up from 28% to 39% (95% CI, 8.0-13.3;P<0.001). Patients with CRT also had a reduction in left ventricular (LV) end-systolic volume from 122.7 to 89.0 mL (95% CI, 28.2-45.8), as well as a reduction in LV end-diastolic volume from 171.0 to 143.2 mL (95% CI, 22.1-41.6; P<0.001 for both).

Treatment-related adverse events included a procedure-related pneumothorax (n=1), a device pocket infection (n=1), and heart failure requiring hospitalization during follow-up (n=1).

The study is limited by its small patient cohort, short duration of follow-up, and lack of control group.

See the article here:
Cardiac Resynchronization Therapy Helps Cancer Survivors With Heart Failure - DocWire News

Read More...

Opinion: Personalized Medicine Is The Solution To Modern Cancer Treatment – BioSpace

Friday, November 15th, 2019

The following is an opinion article written by Laura Towart, CEO and founder of My Personal Therapeutics, a London based digital health company offering advanced personalized cancer therapeutics. Their Personal Discovery Process uses fruit fly avatars to genetically mimic a patients cancer to identify drug combinations against the specific cancer. You can learn more about the company by reading this BioSpace article or going to their website.

The medical sector is getting carried away with a one size fits all approach to cancer treatment.

A cancer diagnosis simply means the patient has a condition that propagates abnormal cells within their body. This conditions underlying cause and characteristics will naturally differ between patients, but oncologists tend to prescribe a shockingly consistent course of treatment: anti-cancer medication and a course of chemotherapy. An estimated 1,735,350 Americans were diagnosed with cancer in 2018, but 1.7 million people cant all be the same.

Consumers have come to expect high levels of personalization from their smartphones, home designs, and online shopping experiences, and end up enjoying these things more as a result. They also deserve a personalized approach in cancer treatment that considers their unique genetic traits and the latest medical research this methodology stands a significantly increased chance of pushing back against the disease.

Personalized medicine tailors medical treatment to each patients unique characteristics

Factoring in conventional data points about the individual patient is just the start: their medical history, which country theyre from, and how physically active they are certainly constitute useful markers to guide treatment. But now its possible to go several layers beyond that and achieve a fuller picture by sampling the patients DNA, gaining a view into the genetic recipe that makes them who they are.

When scientists sequenced the complete human genome in 2003, it unlocked a new era of medical possibilities. There are approximately 3 billion pairs of chemical building blocks (called bases) in the human genome; the order in which they appear reveals the genetic information that each segment of DNA carries. In other words, medical researchers had developed a kind of Rosetta Stone for human genetic information. This forms the underpinning for personalized medicine today.

Medical professionals working in this arena can enhance their understanding of how someones unique molecular and genetic profile might leave them vulnerable to certain diseases or conditions, whether that information was already medically known or not. Where previous approaches to cancer treatment presented oncologists with a set of assumed best practices, personalized medicine gives them a figurative telescope to explore many possible treatments and determine one with an optimal outcome.

Fruit flies can be a powerful weapon for personalized medicine professionals

Medical researchers can use fruit flies to see the future. At the surface level, these kitchen pests have basically nothing to do with human biology, but they actually share up to 75 percent of the genes associated with human disease. Theyre furthermore one of the most genetically malleable organisms out there, capable of handling 15 mutations or more.

They present us with a valuable analog to see how a human body will metabolize and distribute a drug. A tumor generated in the fly gut can resemble a human colorectal tumor. As its inside the body (instead of on a cancer cell culture plate), it actually interacts with other organs in a long-range communication process. In other words, medical researchers like the ones at Mount Sinais Center for Personalised Cancer Therapeutics (CPCT) or at partner company My Personal Therapeutics can direct a genetically similar tumor to grow inside of a fruit fly, then experiment on it to see what kind of treatment works. Because fruit fly lifespans are very short, its easy to do this at a large scale and get meaningful results very quickly.

Personalized medicine will change the way we think about, identify, and manage cancer

Youve probably heard the term big data before in reference to business and internet technology. When the medical world collects highly precise data about individual patients at scale, it effectively lays the foundation for a comparative database that will make high-quality diagnoses quicker and more affordable in the future. In the long term, this will present doctors with trusted shortcuts for providing more accurate cancer treatment.

Imagine that personalized medicine has been the norm for 20 years and every physician has access to data that compares symptoms and treatments across all individuals. Doctors would only need to plug your vital statistics into a database and check them against your declared symptoms in order to see what worked for other people just like you. When I say just like you, I really mean it. This is the value of big data well eventually be able to segment out previous patients of all different demographics with deep specificity.

The future of cancer treatment is much like the future of medicine at large. Its going to depend on highly individualized approaches that harness all of a patients data, from their lifestyle to their genetic code. Genetic methodologies grant medical professionals access to a fuller picture of patient health than theyve ever had before. Its time to start using them on an individual basis in order to ensure high-quality outcomes for cancer patients.

You dont need to be a medical expert to know one size doesnt fit all.

Go here to see the original:
Opinion: Personalized Medicine Is The Solution To Modern Cancer Treatment - BioSpace

Read More...

A Revolution in the Creation of Scientific Workplaces – Scientific American

Friday, November 15th, 2019

In todays hypercompetitive research environment, successful organizations know strategic workplace design is no longer a luxury. Historically, providing a private office and a large wet lab were enough to attract great talent and achieve expected results.

However, todays researchers are challenging the status quo as they seek creative ways to perform their work. These researchers are looking for workspaces that enable new levels of collaboration, creativity, flexibility and well-being. Convergent scientific workplace design is based on the widely recognized convergence research model that has been proven to break down traditional barriers of scientific discovery and pave the way toward improved recruitment, retention, productivity and innovation.

WHAT IS CONVERGENCE RESEARCH?

Scientific research is undergoing a transformational change. Highly specialized gene therapies now cure once incurable cancers. Personalized medicine and big data help doctors treat and prevent diseases better than ever before. The ever-advancing technologies behind these breakthroughs are driving a new paradigm of cutting-edge, integrated research across multiple fields and industries that have been historically distinct disciplines. Many have defined this shift as the convergence revolutionone that shares methods and ideas from chemists, mathematicians, economists, computer scientists, biologists, physicists, engineers and more to improve the lives of millionsif not billionsof people.

Many initiatives are underway to expand awareness and encourage more scientists to adopt the convergence model of research. The National Science Foundation (NSF) has identified convergence research as one of its 10 Big Ideas for the agency and is creating a solicitation process to encourage convergence in a subset of its research and center awards. The National Academies Government-University-Industry Research Roundtable and the National Academy of Sciences have held formal workshops on the topic.

WHY IS WORKPLACE DESIGN IMPORTANT?

In this convergence research model, the scientific workplace environment is more important. With so many disciplines sharing the same spaceall with different needs and ways of workingand more remote team members needing means to collaborate, it is important for institutions to understand the role facility design can play in its success or failure. When we talk about optimizing the workplace environment, we are ultimately talking about the researchers within. They are the factors that influence performance, innovation and retentionall of which are measures of success for a research institution.

The cost of unhappy researchers can be devastating. In a paper titled Innovation spaces: Workspace planning and innovation in U.S. university research centers, researchers Umut Toker and Denis Gray cite that over a period of 10 years, operating and maintenance costs of an organization remain around 8 percent, whereas human costs remain around 85-90 percent. It is much more advantageous for institutions to focus on long-term productivity, increased collaboration, and reduction of turnover to reduce cost rather than focusing on the short-term, operational and maintenance of the facility itself.

Sometimes it is seemingly more difficult to demonstrate how workplace planning can influence innovation in an organization. Toker and Grays study proved this correlation through data analysis that there is a significant relationship between workspace planning, consultations and innovation process outcomes, citing that university research centers featuring overall high configurational accessibility, shorter walking distances and intact territories exhibit higher face-to-face consultation rates, consultation network connectivity, and subjective/objective innovation process outcomes.

WHAT DESIGN STRATEGIES CAN IMPROVE RESEARCH OUTCOMES?

When renovating or creating a new research work environment, there are three important design strategies to consider that can ultimately affect research outcomes.

Collaboration

Far too often, scientists are separated from each other in formally arranged spaces, reflecting linear processes and static functionality, and status is reflected by size of internal real estate and the allocation of enclosed offices. The convergence research environment embraces new methodologies of working where multidisciplinary teams can come together away from their departmental homes. Through design, we can encourage informal social interactions and foster intentional collisions of people with diverse backgrounds and skill sets to catalyze innovation.

In order to foster social ties, workplaces should make it easier for people to interact and provide places where people are comfortable talking about things other than work. One tactic is to create social spaces at intersections where people are likely to bump into acquaintances with whom they may not regularly work. To enhance the impact of central social spaces, these informal collaboration areas should be highly visible, located along central circulation paths and within reasonable walking distances of key collaborators. In addition, these spaces should have amenities such as coffee, snacks, seating and comfortable standing gathering areas.

A study at the University of Michigan supports co-locating team members, finding that researchers who occupy the same building are 33 percent more likely to form new collaborations than researchers who occupy different buildings, and scientists who occupy the same floor are 57 percent more likely to form new collaborations than investigators who occupy different buildings.

Example: Johns Hopkins University Applied Physics Laboratory, Building 201, Laurel, MD

Johns Hopkins University Applied Physics Laboratory Building 201 is an interdisciplinary research facility that will provide flexible laboratory and office space in a highly collaborative, open workplace environment. The laboratories are organized in a shared facility plan, which features glass enclosures that promote more interaction. They are designed around a four-story daylit atrium in conjunction with generous, unassigned collaborative spaces offering researchers many options for focused, informal and group work activities. Cafs are on every floor, which promote greater interactions between researchers from different departments. When complete, there will be over 50 different collaboration environments and over 20 different laboratory environments suited to fit researchers needs.

Flexibility

The performance of researchers is optimized when they feel they have some control over the physical conditions they experience there. Permanent fixtures and traditional laboratory layouts were designed for the slower-moving research of the past. However, researchers today are more mobile, more agile and desire a workplace that can be quickly and easily optimized for their needs. Flexibility within laboratories includes a multitude of integrated design approaches, including flexible engineering systems, modularity of furniture and casework, and accessibility. Key to accommodating flexibility is designing spaces that can easily transform when new processes are realized or new breakthroughs are discovered.

There should be a fluid mix of wet and dry spaces in a convergence research laboratory. This level of flexibility is beneficial because researchers in a convergence model are just as likely to be doing wet bench work as they are to be doing prototypes, physical and virtual simulations, data informatics and data analysis. Having the wet bench in close proximity to dry labs (and write-up areas) allows researchers to move quickly from task to task, without having to leave their floor or building.

Flexibility is the physical expression of convergence research. If we expect researchers to think broadly outside of their particular domains of expertise, we need to provide them spaces to interact and work alongside a wide-ranging team from traditional wet bench scientists to anthropologists.

A universal bench layout is also advised to increase flexibility. Using a best practice in the health care field, an overhead service boom can support the flexibility of a bench layout, which serves power, data and lab gases. Task lighting can also move with the furniture to ensure a consistently high-quality visual experience regardless of physical location.

Example: CJ Blossom Park, Suwon, South Korea

The 1.2 million sf building consolidates CJ Corporations previously disparate pharmaceutical, biotechnology, and food products businesses into a single location, enabling it to create industry-defining product strategies and increase its global competitiveness. The design team tested and explored a multitude of bench layouts through the design phase A universal bench design changes the traditional 6 wide x 2.5 deep bench to 5 x 2.5 so it is non-directional and can be configured in parallel or perpendicular direction. These are used throughout the building for both instrumentation and desk activities and provides greater flexibility and encourages more open teaming spaces.

The universal benches are all on wheels, which enable users to configure benches in several different wayslinear, T shaped, U shaped, or L shapedbased on team, project and process. The universal bench can be used for both instrumentation and desk activities. This allows even greater flexibility to scale up or down instrumentation or headcount for a multitude of changing environments such as contractors or summer interns. This also eliminates the need of write-up space in the lab and encourages more open teaming spaces.

Wellness

Lastlyand possibly most importantlyis the focus on researcher wellness. There is an incredible body of work that proves the correlation between the design of the workplace and the quality of work done by the people in it. Gone are the days of researchers tolerating a workplace in the basement. Despite strict environmental requirements in many spaces, researchers nevertheless are expecting workplaces that deliver on their wellness needs. Research space needs to focus on human health through strategies such as natural light, soft seating and acoustics. Researcher comfort and satisfaction are crucial, as it can greatly influence recruiting and retention as discussed above.

Ample access to daylight has proven time and again its benefits in the workplace. In a laboratory setting, this may prove more difficult due to challenges like photosensitive materials handling and glare concerns. However, there are design strategies that can improve daylight access. Consider orienting seating perpendicular to exterior windows. Provide shading devices, particularly on south and west facing windows. Place light sensitive equipment in the center of the floorplate away from the exterior. Consider borrowing daylight into labs from write-up areas and offices.

Noise control has also proven critical to workplace wellness. This factor is often overlooked or is taken out of the design as a cost-saving measure, but it is highly important and should be seriously considered when designing a laboratory environment. Noise reduction strategies can include creating equipment rooms for loud, noisy equipment like minus 80 degree F freezers. Break down large, open labs by zoning into smaller spaces through glass walls, demountable walls, or floor-mounted equipment (like fume hoods). Finally, consider acoustics in ceiling and floor selection.

Example: Novartis-Penn Center for Advanced Cellular Therapies (CACT), Philadelphia

Located on Penn Medicines campus in Philadelphia amidst both clinical care and laboratory facilities, the 30,000 sf Center for Advanced Cellular Therapies (CACT) brings together Penn Medicines intellectual resources combined with pharmaceutical industry leader Novartis with the mutual goal of expediting the development of novel gene therapies for complex diseases of all kinds. To take advantage of the natural light and views, the processing cells are located on the perimeter using a double-wall construction design that provides the necessary isolation of the controlled environment. Additionally, to shield the material from ultraviolet rays, the design team installed polarized film on the windows for some of the most sensitive rooms in the facility so that, with a flick of a switch, the polarization is activated.

Convergence research is the future of science. It is not easy to bring together the strengths of many disciplines; however, it is necessary to help solve the incredibly complex challenges of today and tomorrow. Convergent scientific workplaces can be designed to promote collaboration, flexibility and wellnessall of which can lead to better research outcomes.

For more information on this topic, please see this white paper.

View original post here:
A Revolution in the Creation of Scientific Workplaces - Scientific American

Read More...

Personalized Medicine Market 2019| In-depth Analysis by Regions, Production and Consumption by Market Size, and Forecast to 2026 | Research Industry…

Friday, November 15th, 2019

The Global Personalized Medicine Market (2019 2026) research offers a basic overview of the industry including definitions, applications, classifications, and market chain structure. Moreover, in the global Personalized Medicine Market report, the key product categories of the market are included. The report comparably demonstrates supportive data related to the dominant players in the market, for instance, product offerings, segmentation, revenue, and business synopsis. The global Personalized Medicine Market is as well analyzed on the basis of numerous regions. The firstly the report describes the market overview, cost structure, upstream, and technology. The second part describes the global Personalized Medicine market by key players, by application and type.

Request For Sample PDF Report (Kindly Use Your Bussiness/Corporate Email Id to Get Priority): http://researchindustry.us/report/personalized-medicine-market-ric/773699/request-sample

Competitive Analysis

The global Personalized Medicine market report wraps scope and product overview to define the key terms and offers comprehensive information about market dynamics to the readers. This is trailed by the regional outlook and segmental analysis. The report also consists of the facts and key values of the global Personalized Medicine market in terms of sales and volume, revenue and growth rate.

One of the important factors in the global Personalized Medicine market report is competitive analysis. The report covers all the key factors, such as product innovation, market strategies of the key players, market share, revenue generation, latest research and development, and market expert views.

The followingTopmanufacturersare assessed in this report:

Abbott LaboratoriesAgilent TechnologiesAmgenAstellas PharmaAstrazenecaBayer AGCelgene CorporationGlaxosmithkline PlcIlluminaJohnson & JohnsonLaboratory CorporationMerckNovartis AGRoche Holding AGSiemens AGTakeda Pharmaceutical Company Limited

Personalized Medicine Market Segmentation

For the better grasp insight of the market, this report has provided a detailed analysis of drivers restraints, and trends that dominate the present market scenario and also the future status of the global Personalized Medicine market during the projected period of 2018-2026.

Market Analysis by Product Type

Personalized Medicine DiagnosticsPersonalized Medical CarePersonalized Medicine TherapeuticsPersonalized Nutrition and Wellness

Market Analysis by End-User Application

OncologyCentral Nervous System (CNS)ImmunologyRespiratoryOther Applications

While classifying these segments, the expert team of analysts has listed the relative contribution of each segment for the growth of the global Personalized Medicine market. Detail information of segments is required to recognize the key trends influencing the global market for the Personalized Medicine.

Each segment of the market provides a piece of in-depth information on the qualitative and quantitative aspects of the market. While giving a brief idea about the revenue opportunities for all the segments, this report has also provided the value of absolute dollar opportunity for all the segments over the predicted period of 2018 2026.

Regional Analysis

The significant regions covered in the reports of the global Personalized Medicine market are North America, Europe, the Asia Pacific, South America, and the Middle East and Africa. The market information not only provides the market data of the five geographies as a whole, but it also provides you qualitative as well we qualitative information on country level bifurcation. Adding to that, economic, technological, cultural and social aspects along with the regulatory barriers are entirely analyzed to understand the thorough market scenario across different geographies.

The key highlight of the Research:

Key Questions Answered:

Get In Touch!

Navale ICON IT Park,

Office No. 407, 4th Floor, Mumbai Banglore Highway, Narhe, Pune

Maharashtra 411041

phone +91-020-67320403

Email help@researchindustry.us

Original post:
Personalized Medicine Market 2019| In-depth Analysis by Regions, Production and Consumption by Market Size, and Forecast to 2026 | Research Industry...

Read More...

UC Davis leads in innovative gene editing research with NIH grants – The Aggie

Friday, November 15th, 2019

Researchers strive to address societal health issues through gene editing

In October, three researchers at UC Davis were awarded a $1.5 million grant to fund their project which attempts to demonstrate the effectiveness of gene editing through use of CRISPR, a powerful technology that allows alteration of DNA sequences to change gene function.

This kind of design can help enhance personalized medicine, said R. Holland Cheng, a professor of molecular and cellular biology in the College of Biological Sciences. Specific patients with specific illnesses can be treated in specific ways.

Cheng, along with Kit Lam, a distinguished professor and chair of the Department of Biochemistry and Molecular Medicine in the School of Medicine, and David Segal, a professor in the Department of Biochemistry and Molecular Medicine, were awarded this highly competitive and sought-after grant from the National Institute of Health (NIH).

UC Davis is part of the NIHs Somatic Cell Genome Editing (SCGE) consortium which has awarded grants to 45 other research institutes across the nation so they can begin groundbreaking work on gene editing. Through this consortium, the NIH hopes to find an efficient and safe way to conduct gene editing. Research programs are investigating the best delivery mechanism as well as the most dynamic gene editing tool.

The major problem with gene editing currently is the inability of cells to be edited within a living organism. It has become fairly easy and efficient to edit genes in a cell culture outside of the body but extremely difficult to do the same processes inside the body. Cheng, Lam and Segal are focused on changing this.

The question is how to do it inside of an animal and eventually a human, Lam said.

They are answering this question by utilizing Chengs work in engineering a non-toxic nanoparticle that they hope can transport the gene editing tool CRISPR into the cells of a living organism. Cheng has been able to create a Hepatitis E viral nanoparticle (HEVNP) that when manipulated could be a delivery system for CRISPR. They plan to take this nanoparticle and encase CRISPR inside of it, producing a mechanism for delivery of CRISPR.

The Hepatitis E nanoparticle has the capacity to be a highly efficient way to deliver gene editing to cells in the body due to its unique nature. HEVNP is resistant to the gastric acid environment of the intestines and stomach, enabling it to survive once its entered the body. Given its resistant abilities, HEVNP can be taken orally, making it a useful form of medicine. If able to successfully get HEVNP to the target cells in the body and deploy CRISPR, gene editing abilities could drastically change.

The addition of a cell-type specific targeting ligand to the HEVNP would code the nanoparticle to deliver CRISPR to a specific cell. The abilities of this method to be precise and safe will determine its success.

With five years of funding from the NIH, these three researchers are eager to begin work on this project and see the strides that can be made in gene editing. They have impressive goals for this research, as it has the capacity to reshape medicine.

This will redefine precision medicine as currently there is broad medicine that can cause side effects to people and not be effective, yet by making it specialized it is becoming more precise and effective, Cheng said.

As more effective and safe tools to cure illnesses are being tested and created, the benefits to society could be expansive. With so much potential to help improve the health of society, the NIH is dedicated to coming to new solutions at a quick rate. All programs that received grants will be required to share and utilize the research occurring at other funded programs. The NIH is hoping to eliminate the private nature of research through enforcing the sharing of ideas, as scientists are often constrained by the institutions they work for. It is their hope that by having communication between the programs, positive results will arise faster.

I think this is great because scientists inherently want to work with each other but have real world concerns especially with money, Segal said.

The research results, when groundbreaking, can provide incredible monetary gains and credibility to the institutions that made the discovery. Ultimately, scientists collaborating with one another will serve society as people are able to benefit earlier from this innovative research.

We want the public to know that we are working in their best interest, Segal said.

The NIH grant is competitive and still the third research program to join the consortium at UC Davis. Innovation has never been more prevalent than in this field at UC Davis. With three different programs researching gene editing, UC Davis stands out as a hotspot for this field of research.

Written by: Alma Meckler-Pacheco science@theaggie.org

Go here to see the original:
UC Davis leads in innovative gene editing research with NIH grants - The Aggie

Read More...

Wearables and Healthcare: The 3 Companies Leading the Way – Nasdaq

Friday, November 15th, 2019

Initially seen as a fashion accessory, smartwatches and fitness bands have now entered the healthcare ecosystem. By leveraging advanced technologies such as Artificial Intelligence (AI), Cloud, Machine Learning, Big Data and Analytics, these wrist-worn devices are becoming more sophisticated and relevant in the present day by providing actionable insights and prescriptive measures for end users. This has also ushered in technology giants such as Apple, Samsung and Google in the healthcare space.

Heres a look at the fast-growing wrist-wear market in the backdrop of the digital health space

The increasing focus on personalized care, early detection, and precision medicine along with rising health consciousness is driving the demand for healthcare-related wearables and applications. Asurveyby Accenture shows that the use of wearable devices by consumers has nearly quadrupled in the four year period (2014-2018), from just 9% in 2014 to 33% in 2018. Further, roughly three-fourths of health consumers view wearables such as those that monitor glucose, heart rate, physical activity and sleep as beneficial to understanding their health condition (75%), engaging with their health (73%), and monitoring the health of a loved one (73%).

The smartwatch market is growing at a fast pace and isexpectedto reach a market value of $130.55billion by 2024 from $48.14billion in 2018, registering a CAGR of 18.23% during the forecast period (2019-2024).

Together, Apple, Samsung and Fitbit capture 72% of the market.

In 2018, Apple (AAPL)receivedDe Novo classification for the ECG app and the irregular heart rhythm notification from the Food and Drug Administration (FDA). The AppleWatchis capable of generating an ECG similar to a single-lead electrocardiogram; it can check the heart rate and alert a person about any irregularities. The Apple Watch comes with a vital fall detection feature and can even provide insight to women about their menstrual cycle. Not just smartwatches, Apple is working across the healthcare technology segment, something which has been echoed by Tim Cook in one of his interviews where hesaid, If you zoom out into the future, and you look back, and you ask the question, What was Apples greatest contribution to mankind? It will be about health.

Apples arch rival in the smartphone space, Samsung (SSNLF) is one of its closest competitors in the wrist wearables space as well. Samsung smartwatches help track heart rate, stress levels, sleep, water intake and much more. In June this year, the Galaxy Watch Activerevealedits anytime, anywhere blood pressure-checking capability using My BP Lab 2.0.

The global smartwatch shipments grew an impressive 42% annually to reach 14 million units in the third quarter of 2019. Apple Watch maintained first position with 48% global smartwatch market share, while Samsung held second place, and Fitbit (now acquired by Google) ranks at third,accordingto Strategy Analytics.

Fitbit (FIT) once enjoyed being the uncrowned king of the wearable device market, controlling a major market share untilthe Apple Watch came on the scene, and the dynamics started to change. Fitbitsold22.3 million connected health and fitness devices in 2016, while the same dropped to 13.9 million in 2018. The limited functionality of a fitness band when compared to a smartwatch has been a major reason for Fitbits shrinking market share. A CCS reporthighlights, Western consumers now find less value in the simple fitness bands, even with the added convenience of long battery life, preferring to move on to smartwatches, which offer all the functionality of fitness trackers and so much more.

Earlier this month, Google (GOOG,GOOGL) entered into a definitive agreement to acquire Fitbit for $2.1 billion. Over the years, Fitbit has sold more than 100 million devices and utilizes data to deliver unique personalized guidance and coaching to its users. While, Google introducedWear OSby Google back in 2014, and has been makingadvances in medical technologybut not particularly in wearables. Fitbit gives Google the opportunity to expandfurtherinto the wearables segment as well as introduce Made by Google wearable devices into the market.Back in 2018, Fitbit and Google collaborated to explore the development of consumer and enterprise health solutions. Last month, Fitbitannouncedan alliance with Bristol-Myers Squibb and Pfizer to help drive timely diagnosis of atrial fibrillation (AFib) with the aim of improving earlier detection in individuals at increased risk of stroke.

Fitbit and Google together can become a significant competitor to the existing market leaders in the wrist-wearables space. Wearables will assume a more significant role in the healthcare ecosystem and become a significant revenue generator for the technology providers. WHO Director-General Dr. Tedros Adhanom Ghebreyesus summarizesthe role of digital health technologies: Harnessing the power of digital technologies is essential for achieving universal health coverage. Ultimately, digital technologies are not an end in themselves; they are vital tools to promote health, keep the world safe, and serve the vulnerable.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Read more here:
Wearables and Healthcare: The 3 Companies Leading the Way - Nasdaq

Read More...

Lifebit and Medley Genomics Partner to Deliver Streamlined Solution Supporting New Diagnostic and Therapeutic Discoveries – BioSpace

Friday, November 15th, 2019

Researchers can now tap new disease discoveries using Medley Genomics HotNet2 at enterprise scale, over any system, across distributed data with Lifebit CloudOS

LONDON, UK - Nov 14, 2019 - Lifebit Biotech, a leading innovator in bioinformatics and cognitive software solutions, and Medley Genomics, a company focused on using advanced data analytics to support better diagnosis and treatment of complex diseases, announced today their partnership agreement. The Lifebit-Medley partnership aims at removing the barriers impeding progress in precision medicine where advanced biomedical analysis tools, like HotNet2, must be deployed over distributed and complex data to arrive at breakthrough insights.

Lifebit CEO, Dr Maria Chatzou Dunford, said, We are thrilled to announce our partnership with Medley Genomics, which allows us to bring advanced tools to the biomedical research community, advancing knowledge by powering the investigation of new diagnostic and therapeutic opportunities. Any company or researcher can now discover disease driver genes and novel pathways by utilising the high performance HotNet2 at enterprise scale and over distributed cohorts of patient data without needing to move the data.

Developed by Medley co-founder Dr Ben Raphael, HotNet2 assesses the complex heterogeneous genomic landscape across patient cohorts, including the long tail of disease relevant genes, by building significantly mutated gene subnetworks based on mutational frequencies and known interaction networks. Because HotNet2 comes with many dependencies, installation was complex without Lifebit CloudOS. To increase the power of analysis, experimental setups need to include as many samples as possible. Unless users have endless resources to spend on sequencing and data generation, they would need to combine disconnected data from various public and private sources, presenting a major obstacle to progress.

With Lifebit CloudOS, HotNet2 now runs over distributed data using federated capabilities, providing immediate access to infinite compute resources, said Dr Patrice Milos, Medley Genomics CEO. Increasingly our customers are applying HotNet2 to define subgroups within their patient disease cohorts and to reveal novel biological pathways. Our partnership with Lifebit enables us to reach countless more researchers across our shared communities helping them to simplify their work processes and ultimately bring important discoveries to patients faster.

By deploying HotNet2 with Lifebit CloudOS, analyses are seamlessly executed and distributed data is united through federated analysis - data is never transferred and security is assured. This is critical as analyses can run at sample-level within the users cohort or across different patient cohorts, without compromising the data by moving them outside their secure environment. Detailed reports can be generated at scale, including visualisations for each run, and instantly shared for true collaboration across teams. The HotNet2 solution is available to anyone via the Lifebit CloudOS Marketplace.

View pan-cancer HotNet analysis here.Try cloud-native HotNet2 here.

ABOUT LIFEBITLeading life sciences organisations are accelerating their research and discoveries with Lifebit. Lifebit CloudOS is the federated, integrated solution for fully FAIR omics and biomedical analysis, allowing anyone to streamline and scale analyses faster, cheaper, and securely in their own data environments. Lifebit AI-Engine has deep-learned the biology behind drug response and is helping pharmaceutical companies repurpose drugs, validate targets and optimise vaccines by reasoning about omics data like humans would. Headquartered in London, UK, Lifebits ecosystem of employees, partners, and customers spans 15 countries. Visit lifebit.aiLifebit press contact: pr@lifebit.ai

ABOUT MEDLEY GENOMICSMedley Genomics Inc., based in Providence, Rhode Island, US, provides cutting edge algorithms and software to deliver on the promise of individualization of therapy. The companys approaches provide deep insight into the heterogeneity of disease as well as defining unique disease mechanisms across disease cohorts. Applied first in oncology, these insights are necessary for optimizing targeted and combination therapies, personalized cancer vaccines and immunotherapies to effectively treat the total disease burden and offer hope of lasting cures for patients. Visit Medleygenomics.comMedley press contact: info@medleygenomics.com

See the article here:
Lifebit and Medley Genomics Partner to Deliver Streamlined Solution Supporting New Diagnostic and Therapeutic Discoveries - BioSpace

Read More...

SLC22A1 And ATM Genes Polymorphisms Are Associated With The Risk Of Ty | TACG – Dove Medical Press

Friday, November 15th, 2019

Rana M Altall,1 Safaa Y Qusti,1 Najlaa Filimban,2 Amani M Alhozali,3 Najat A Alotaibi,4 Ashraf Dallol,2 Adeel G Chaudhary,2 Sherin Bakhashab1,2

1Department of Biochemistry, Faculty of Science, King Abdulaziz University, Jeddah 21589, Kingdom of Saudi Arabia; 2KACST Technology Innovation Center in Personalized Medicine, King Abdulaziz University, Jeddah 21589, Kingdom of Saudi Arabia; 3Department of Internal Medicine, Faculty of Medicine, King Abdulaziz University, Jeddah 21589, Kingdom of Saudi Arabia; 4Department of Family and Community Medicine, Faculty of Medicine, King Abdulaziz University Hospital, Jeddah 21589, Kingdom of Saudi Arabia

Correspondence: Sherin BakhashabKing Abdulaziz University, P.O. Box 80218, Jeddah 21589, Kingdom of Saudi ArabiaTel +966 12 6400000Fax +966 12 6952076Email sbakhashab@kau.edu.sa

Introduction: Type 2 diabetes mellitus (T2DM) is a major global health problem that is progressively affected by genetic and environmental factors. The aim of this study is to determine the influence of solute carrier family 22 member 1 (SLC22A1) rs628031 and rs461473, and ataxia telangiectasia mutated (ATM) rs11212617 polymorphisms on the risk of T2DM in Saudi Arabia by considering many parameters associated with glycemic control of T2DM, such as body mass index (BMI), fasting blood glucose, glycated hemoglobin (HbA1c), and triglyceride.Methods: In a case-control study, genomic DNA from controls and diabetic groups was isolated and genotyped for each single-nucleotide polymorphism.Results: There were significant correlations between T2DM and both BMI and HbA1c. Significant associations between G/G and A/G genotypes of rs628031 and rs461473 variants of SLC22A1 and high levels of HbA1c were detected. Therefore, G was predicted to be the risk allele among the assessed SLC22A1 variants. A significant correlation was observed between A/A and A/C genotypes of the rs11212617 polymorphism of ATM and elevated HbA1c. Relative risk calculation confirmed A to be the risk allele in the T2DM population.Conclusion: Our study showed the risk of the assessed SLC22A1 and ATM variants on glycemic control parameters in diabetic patients.

Keywords: type 2 diabetes mellitus, single-nucleotide polymorphism, solute carrier family 22 member 1, ataxia telangiectasia mutated

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Link:
SLC22A1 And ATM Genes Polymorphisms Are Associated With The Risk Of Ty | TACG - Dove Medical Press

Read More...

Anatomic Pathology Market – Global Forecast to 2024: High Incidence of Cancer and Other Target Diseases Drives Growth – ResearchAndMarkets.com -…

Friday, November 15th, 2019

DUBLIN--(BUSINESS WIRE)--The "Anatomic Pathology Market by Product & Service (Instruments (Tissue Processing Systems, Microtomes), Consumables (Antibodies), Histopathology), Application (Disease Diagnosis (Cancer (Gastrointestinal)), End User (Hospital, Lab) - Global Forecast to 2024" report has been added to ResearchAndMarkets.com's offering.

The anatomic pathology market is projected to reach a value of USD 44.4 billion by 2024 from USD 33.0 billion in 2019, at a CAGR of 6.1% during the forecast period.

The growth in this market is attributed to the high incidence of cancer and other target diseases, availability of reimbursement, and the growing focus on personalized medicine.

In addition, emerging economies such as China, India, and Brazil are expected to offer significant growth opportunities for players operating in the anatomic pathology market during the forecast period. However, the availability of refurbished products, the lack of skilled professionals, and product recalls are expected to hamper the market growth to a certain extent in the coming years.

Disease diagnosis segment accounted for the larger share of the anatomic pathology market, by application, in 2018

Based on application, the anatomic pathology market is segmented into disease diagnosis and medical research. In 2018, the disease diagnosis segment accounted for the larger market share, due to the rapid growth in the geriatric population and the increasing incidence of cancer and other chronic diseases.

Hospital laboratories to register the highest growth in the anatomic pathology market during the forecast period

Based on end-user, the anatomic pathology market is segmented into clinical laboratories, hospital laboratories, and other end users. The hospital laboratories segment accounted for the largest market share in 2018 and is projected to register the highest CAGR during the forecast period. The growth of this segment can be attributed to the increasing number of patient visits to hospitals, a growing number of in-house diagnostic procedures performed in hospitals, growing awareness regarding early disease diagnosis, and the availability of reimbursements in developed markets for clinical tests performed in hospitals.

North America will continue to dominate the anatomic pathology market during the forecast period

Geographically, the anatomic pathology market is segmented into North America, Europe, the Asia Pacific, and the Rest of the World. In 2018, North America accounted for the largest market share, followed by Europe. Factors such as the rising prevalence of chronic diseases, increasing healthcare expenditure, the high-quality infrastructure for hospitals and clinical laboratories, and the presence of major market players in the region are driving the growth of the anatomic pathology market in North America.

Market Dynamics

Drivers

Opportunities

Challenges

Trends

List of Companies Profiled in the Report

For more information about this report visit https://www.researchandmarkets.com/r/i0353n

Read the original post:
Anatomic Pathology Market - Global Forecast to 2024: High Incidence of Cancer and Other Target Diseases Drives Growth - ResearchAndMarkets.com -...

Read More...

Personalized Medicine Market Analysis by Top Companies, Driver, Existing Trends and Global Forecast by 2026 – WindStreetz

Friday, November 15th, 2019

Personalized Medicine Market Overview:

The Personalized Medicine Market is expected to grow at a significant pace, reports Verified Market Research. Its latest research report, titled [Global Personalized Medicine Market Size and Forecast 2019-2026, Breakdown Data by Companies, Key Regions, Types and Application], offers a unique point of view about the global market. Analysts believe that the changing consumption patterns are expected to have a great influence on the overall market. For a brief overview of the global Personalized Medicine Market, the research report provides an executive summary. It explains the various factors that form an important element of the market. It includes the definition and the scope of the market with a detailed explanation of the market drivers, opportunities, restraints, and threats.

GlobalPersonalized Medicine Market: Segmentation

The chapters of segmentation allow the readers to understand the aspects of the market such as its products, available technologies, and applications of the same. These chapters are written in a manner to describe their development over the years and the course they are likely to take in the coming years. The research report also provides insightful information about the emerging trends that are likely to define progress of these segments in the coming years.

Request a Sample Copy of this report @https://www.verifiedmarketresearch.com/download-sample/?rid=7106&utm_source=WSN&utm_medium=AK

Key Players Mentioned in the Personalized Medicine Market Research Report:

Personalized Medicine Market: Regional Segmentation

For a deeper understanding, the research report includes geographical segmentation of the Personalized Medicine Market. It provides an evaluation of the volatility of the political scenarios and amends likely to be made to the regulatory structures. This assessment gives an accurate analysis of the regional-wise growth of the Personalized Medicine Market.

Personalized Medicine Market: Research Methodology

The research methodologies used by the analysts play an integral role in the way the publication has been collated. Analysts have used primary and secondary research methodologies to create a comprehensive analysis. For an accurate and precise analysis of the Personalized Medicine Market, analysts have bottom-up and top-down approaches.

Ask for Discount @https://www.verifiedmarketresearch.com/ask-for-discount/?rid=7106&utm_source=WSN&utm_medium=AK

Table of Content

1 Introduction of Personalized Medicine Market

1.1 Overview of the Market 1.2 Scope of Report 1.3 Assumptions

2 Executive Summary

3 Research Methodology of Verified Market Research

3.1 Data Mining3.2 Validation3.3 Primary Interviews3.4 List of Data Sources

4 Personalized Medicine Market Outlook

4.1 Overview4.2 Market Dynamics4.2.1 Drivers4.2.2 Restraints4.2.3 Opportunities4.3 Porters Five Force Model4.4 Value Chain Analysis

5 Personalized Medicine Market, By Deployment Model

5.1 Overview

6 Personalized Medicine Market, By Solution6.1 Overview

7 Personalized Medicine Market, By Vertical

7.1 Overview

8 Personalized Medicine Market, By Geography8.1 Overview8.2 North America8.2.1 U.S.8.2.2 Canada8.2.3 Mexico8.3 Europe8.3.1 Germany8.3.2 U.K.8.3.3 France 8.3.4 Rest of Europe 8.4 Asia Pacific 8.4.1 China 8.4.2 Japan 8.4.3 India 8.4.4 Rest of Asia Pacific 8.5 Rest of the World 8.5.1 Latin America 8.5.2 Middle East

9 Personalized Medicine Market Competitive Landscape

9.1 Overview 9.2 Company Market Ranking 9.3 Key Development Strategies

10 Company Profiles

10.1.1 Overview 10.1.2 Financial Performance 10.1.3 Product Outlook 10.1.4 Key Developments

11 Appendix

11.1 Related Research

Complete Report is Available @ https://www.verifiedmarketresearch.com/product/global-personalized-medicine-market-size-and-forecast-to-2026/?utm_source=WSN&utm_medium=AK

We also offer customization on reports based on specific client requirement:

1-Freecountry level analysis forany 5 countriesof your choice.

2-FreeCompetitive analysis of any market players.

3-Free 40 analyst hoursto cover any other data points

About Us:

Verified Market Research has been providing Research Reports, with up to date information, and in-depth analysis, for several years now, to individuals and companies alike that are looking for accurate Research Data. Our aim is to save your Time and Resources, providing you with the required Research Data, so you can only concentrate on Progress and Growth. Our Data includes research from various industries, along with all necessary statistics like Market Trends, or Forecasts from reliable sources.

Contact Us:

Mr. Edwyne Fernandes Call: +1 (650) 781 4080 Email:sales@verifiedmarketresearch.com

Tag: Personalized Medicine Market Size, Personalized Medicine Market Growth, Personalized Medicine Market Analysis, Personalized Medicine Market Forecast, Personalized Medicine Market Outlook, Personalized Medicine Market Trends, Personalized Medicine Market Research, Personalized Medicine Market Report

Read the original:
Personalized Medicine Market Analysis by Top Companies, Driver, Existing Trends and Global Forecast by 2026 - WindStreetz

Read More...

Mosunetuzumab Induces Complete Remissions in Poor Prognosis Non-Hodgkin Lymphoma Patients, Including Those Who Are Resistant to or Relapsing After…

Friday, November 15th, 2019

Introduction:Improved treatments are needed for relapsed or refractory (R/R) non-Hodgkin lymphoma (NHL) pts. Options are particularly limited for pts with B-cell NHLs who are R/R to CAR-T therapies or for whom a delay in effective therapy precludes this approach. Mosunetuzumab (M; RG7828) is a full-length, fully humanized immunoglobulin G1 (IgG1) bispecific antibody targeting both CD3 (on the surface of T cells) and CD20 (on the surface of B cells). In an ongoing Phase I/Ib study (GO29781; NCT02500407), promising efficacy and favorable tolerability were observed in R/R NHL pts (Budde et al. ASH 2018; Bartlett et al. ASCO 2019). We report complete remissions (CRs) with M in NHL pts who are R/R to CAR-T therapy, as well as activity with M re-treatment.

Methods:GO29781 is an open-label, multicenter, Phase I/Ib, dose escalation and expansion study of M in R/R B-cell NHL. Data is presented from Group B, in which M is administered with step-up dosing on Days 1, 8, and 15 of Cycle 1, and then as a fixed dose on Day 1 of each subsequent 21-day cycle (maximum 17 cycles). Outcome measures include best objective response rate (ORR) by revised International Working Group criteria, maximum tolerated dose (MTD), and tolerability.

Results:As of June 4, 2019, 218 pts in Group B had received any amount of M. Indolent NHL (iNHL) pts (n=72) were mainly follicular lymphoma (FL, n=69). Aggressive NHL (aNHL) pts (n=141) were mainly diffuse large B-cell lymphoma (DLBCL, n=87) or transformed FL (trFL, n=29). Median prior systemic therapies was 3 (range: 1-14). Twenty-three pts had prior CAR-T therapy (12 DLBCL, 6 trFL, 5 FL), and 16 were efficacy evaluable (7 DLBCL, 5 trFL, 4 FL). ORR and CR rates were 43.8% (7/16) and 25.0% (4/16, 2 DLBCL and 2 FL), respectively. Expansion of previously administered CAR-Ts after M administration was detected by quantitative PCR, in line with the mechanism of action of M.

Dose escalation is ongoing, supported by a positive exposure-response relationship for efficacy and broad therapeutic window with step-up dosing (Li et al. ASH 2019). Among efficacy-evaluable pts across all dose levels, ORR and CR rates were 64.1% (41/64) and 42.2% (27/64) in iNHL pts and 34.7% (41/119) and 18.6% (22/119) in aNHL pts, respectively.

CRs appeared durable, with 25/27 (92.6%) iNHL pts (median time from first CR: 5.8 months; range: 0.2-28.9) and 15/22 (68.2%) aNHL pts (median time from first CR: 8.8 months; range: 0.0-25.4) who achieved CR remaining in remission. Re-treatment with M was allowed in CR pts who relapsed. Four pts, including 1 in Group A who was initially treated with a fixed, non-step-up dosing schedule, received M re-treatment. One CR and 2 partial responses were observed. All three responses are ongoing, with the CR pt in second remission for 314 days.

The MTD of M has not been reached at doses up to 1/2/60mg (Cycle 1 Day 1, 8, and 15). Adverse events (AEs) leading to treatment withdrawal were uncommon (12/218, 5.5%). Cytokine release syndrome (CRS), graded by Lee criteria (Lee et al. Blood 2014;124:188-95), was observed in 28.4% of pts, and was mostly Grade (Gr) 1 (21.1%) or Gr 2 (6.0%); Gr 3 CRS occurred in 1.4% of pts. Most CRS events occurred in Cycle 1; 5 pts (2.7%) had CRS during or after Cycle 2. Three of 218 pts (1.4%) received tocilizumab for CRS management; all 3 events resolved without sequelae (for 1 pt, CRS resolved after the cutoff date). Neurological AEs (NAEs) were reported in 44% of pts (Gr 1, 28.0%; Gr 2, 12.8%; Gr 3, 3.2%). Common NAEs were headache (14.7%), insomnia (10.1%), and dizziness (9.2%). Potential immune effector cell-associated neurotoxicity syndrome (ICANS)-like NAEs of Gr 1 or Gr 2 confusional state occurred in 3 pts (1.4%) during cycles 1 and 2. The frequency of CRS and NAEs did not correlate with M exposure, likely due to step-up dosing, which effectively mitigates acute toxicities and allows administration of higher doses (Bartlett et al. ASCO 2019; Li et al. ASH 2019). Among the 4 pts who were re-treated with M, no CRS was observed and NAEs were reported in 1 pt (Gr 1 headache and insomnia). Among the 23 pts who were R/R to CAR-T therapy, CRS occurred in 5 pts (21.7%; Gr 1, 13.0%; Gr 2, 4.3%; Gr 3, 4.3%) and NAEs in 8 pts (34.8%; Gr 1, 17.4%; Gr 2, 13.0%; Gr 3, 4.3%), with no ICANS-like events.

Conclusions:M has favorable tolerability and durable efficacy in pts with heavily pre-treated R/R B-cell NHL, including CRs in pts with disease progression after CAR-T therapies. Preliminary data support the possibility for re-treatment with M.

Go here to see the original:
Mosunetuzumab Induces Complete Remissions in Poor Prognosis Non-Hodgkin Lymphoma Patients, Including Those Who Are Resistant to or Relapsing After...

Read More...

Can ‘smart toilets’ be the next health data wellspring? – University of Wisconsin-Madison

Thursday, November 14th, 2019

Wearable, smart technologies are transforming the ability to monitor and improve health, but a decidedly low-tech commodity the humble toilet may have potential to outperform them all.

Thats the conclusion of a team of metabolism scientists at the University of WisconsinMadison and the Morgridge Institute for Research, who are working to put the tremendous range of metabolic health information contained in urine to work for personalized medicine.

Urine contains a virtual liquid history of an individuals nutritional habits, exercise, medication use, sleep patterns and other lifestyle choices. Urine also contains metabolic links to more than 600 human conditions, including some of the major killers such as cancer, diabetes and kidney disease.

The toilet could someday outperform wearable, smart technologies in the ability to monitor and improve health. Photo: Pexels.com

The team has two essential questions. First, can frequent monitoring and testing of urine samples glean useful real-time information about an individuals health? And second, can a technology platform be adapted to toilets that can make the collection process simple, accurate and affordable?

They received some promising answers to the first question in a small pilot study conducted this year, the results of which were published in the Nov. 11 issue of the open access Nature journal npj Digital Medicine. Two research subjects consistently collected all urine samples over a 10-day period and submitted those samples for tests with both gas chromatography and mass spectrometry for a complete readout of their metabolic signatures.

The two subjects also happen to be lead authors on the paper: the Morgridge Institutes Joshua Coon and Ian Miller, data scientist with the Coon research group. Collectively, they provided 110 samples over the 10-day period, and also used wearable technology to track their heart rates, number of daily steps, calorie consumption and sleep patterns.

Joshua Coon believes the smart toilet concept could have major population health implications, possibly providing early warning of viral or bacterial outbreaks.

The results? The samples do indeed contain a remarkable health fingerprint that follows the ebbs and flows of daily life. For example, the subjects kept records of coffee and alcohol consumption, and the biomarkers with a known connection to both of those drinks were abundantly measured. One subject took acetaminophen, which was measured in urine by a spike in ion intensity. They were also able to measure with precision the metabolic outputs from exercise and sleep.

The next step: The research team is designing a smart toilet that will incorporate a portable mass spectrometer that can recognize the individual and process samples across a variety of subjects. They plan to install the toilet in their research building and expand the user group to a dozen or more subjects. Coon says the design is a bit Rube Goldberg-like but functional.

We know in the lab we can make these measurements, says Coon, a UWMadison professor of chemistry and biomolecular chemistry. And were pretty sure we can design a toilet that could sample urine. I think the real challenge is were going to have to invest in the engineering to make this instrument simple enough and cheap enough. Thats where this will either go far or not happen at all.

While the pilot experiment didnt examine health questions, the researchers say many possibilities exist. For example, testing could show how an individual metabolizes certain types of prescription drugs in ways that could be healthy or dangerous. Also, as the population ages and pursues more stay-at-home care, urine tests would indicate whether people are taking their medications properly and if those medications are having their intended effects.

This graphic illustrates how an integrated smart toilet system might work as a real-time method of monitoring health. While the application may be years away, proof of principle is being developed in the lab. Dasom (Somi) Hwang,Joshua Coon Lab

Coon also believes the smart toilet concept could have major population health implications, not unlike the National Institutes of Health All of Us human genome database. If you had tens of thousands of users and you could correlate that data with health and lifestyle, you could then start to have real diagnostic capabilities, he says, adding that it might provide early warning of viral or bacterial outbreaks.

Coon, who runs the National Center for Quantitative Biology of Complex Systems, says the idea of meta-scale urine testing has intrigued him for some time. Josh mentioned this at a group meeting one time and it was met with laughter, Miller recalls. I thought, you know, I kind of like the idea. I already track a lot this stuff in my everyday life.

Adds Coon: So we went out and bought a couple coolers and started collecting.

While the mass spectrometer small molecule analyses are being done on $300,000 machines, Coon says portable mass spectrometer technologies exist at a tenth of that cost. He says that with a market this massive, they could eventually hit a reasonable cost threshold.

Almost every automobile on the road is more complicated than that portable mass spectrometer, he says.

Share via Facebook

Share via Twitter

Share via Linked In

Share via Email

Read the original post:
Can 'smart toilets' be the next health data wellspring? - University of Wisconsin-Madison

Read More...

CDMOs to Benefit From Rising BTDs, Orphan Drugs and Fast Track Status – Contract Pharma

Thursday, November 14th, 2019

CPhI Worldwide has released the fourth part of its 2019 Annual Report. In it experts Peter Soelkner, managing director, Vetter Pharma International; Stuart Needleman, chief commercial officer, Piramal Pharma Solutions; and Adam Bradbury, industry analyst, GlobalData, discuss the future of patient centric CDMOs.In his piece, Bradbury explores how the changing drugs pipeline and increasing diversity of innovators are creating opportunities for the CDMO sector. He asserts that the increase in drug approvals and priority reviews are likely to be beneficial to the CMO industry in the next few years, as manufacturing of these products is often outsourced.In 2018, 34 orphan-designed drug NMEs were approved, the highest between 2009 and 2018; this represented 53% of all NME approvals, said Bradbury. Of these approvals, 65% were outsourced, the strongest outsourcing propensity for orphan NMEs since 2014. Mega cap companies sponsored five Orphan NMEs and only one of these had commercial dose outsourced.Priority review therapies and other accelerated drugs are more likely to be contract manufactured than products that go through standard review. Both small and mid-size cap companies are more likely to outsource their dose manufacturing capabilities and/or expertise. Therefore, small and medium sized pharma companies with priority review therapies represent a likely strong stream of new business for the industry in the near term.According to Bradburys analysis, 23 NMEs were approved with Fast Track status in 2018. This was significantly more than in 2017. Of these products, 70% of them were outsourced, which represents a five-year increase average of 58%. Due to this, the rising number of priority review designations and small cap companies gaining FDA approvals can only be a positive sign for dose CMOs. Similarly, outsourcing percentages for CDMOs of Breakthrough Therapy Designation (BTD) has never been so high. Demand also remains for high potency APIs, of which around 60% are developed for oncology and we continue to see rising demand for CDMOs with containment facilities.In other new implications for the contract services sector, Vetters Peter Soelkner predicts that new drugs will have to be produced using a more patient-centric methodology. Soelkner emphasizes that the use of personalized medicines will mean increasingly individualized dosages and packaging. But he also forewarns that this will necessitate that contract providers and the industry adapt to help reduce the costs per patient.Soelkner says that personalized medicines will require new logistics and manufacturing systems, as each therapy is tailored specifically to an individuals own genetic profile. Looked at more broadly, nearly 40% of the new drug pipeline already involves injectables, and often for smaller patient cohorts. This will continue to present manufacturing challenges, as companies switch from systems designed for larger batches.Such systems will need to allow for the creation of APIs in a small scale and possibly, be directly integrated at the filling site, said Soelkner. However, we believe that for the main disease indications todays existing types of therapies will remain standard procedure. For many diseases individualized personalized medicine is still someway off from becoming clinical routine.Personalized medicine helps avoid unwanted costs for insurance payers, by only prescribing these expensive medications for people who are going to respond to it. But these smaller volume therapies are also simultaneously driving up manufacturing costs per unit for each affected patient. To counter these costs, Soelkner states that increased Digitalization and the use of Artificial Intelligence might help manufacturers and their partners to lower the total cost of production.Digitization and Artificial Intelligence innovations may help manufacturers and their partners enhancing overall productivity and improve cost effectiveness in the future, he said.Stuart Needleman, chief commercial officer, Piramal Pharma Solutions, explores how the patient-centric journey will operate through the pharmaceutical supply chain. He states that there will be a progressive trend across the pharmaceutical industry, with a shift towards lower volume targeted therapies. This has been driven by an increasing amount of research into more complex drugs and compounds.Needleman argues that one approach is to deliver new ways of motivating the workers so that they have a real understanding of the importance of their work and the effect on real world patients.At Piramal Pharma Solutions, Patient Awareness Councils are being introduced across global sites in order to deliver true patient centricity. According to Needleman, These new bodies comprise cross-functional executives and employees, and they act as the patients advocates and ambassadors for patient centricity though development and commercialization. Moving forward in the future, they will have an extremely important role to play in every project, and are tasked with creating, managing and monitoring the best practices for applying patient-centricity to the entire organization.In another emerging patient focused trend on the rise, Needleman also reports that patients are seeking a greater deal of information, calling them the globally informed patient. Consequently, to help improve transparency, we may even see license holders share and celebrate the manufacturing records of CDMO partners.Orhan Caglayan, CPhIs brand directory, added, These results mirror what we are seeing at ICSE the worlds largest contract services exhibition where our exhibitors are reporting robust growth in demand, especially for smaller and medium pharma customers who need specialist partners to help discover, develop and manufacture therapies. It is, of course, also why our event is crucial, as we bring together the contract services community so that attendees can meet multiple potential contract services partners, while also learning about the main trends in the industry. In the next few years, we anticipate extremely good growth for our contract service specialists and we will continue to adapt our content to showcase the newest technologies that help pharma customers advance products more quickly to patients.The complete findings of the CPhI Annual Report are available for free here.

Read more from the original source:
CDMOs to Benefit From Rising BTDs, Orphan Drugs and Fast Track Status - Contract Pharma

Read More...

Halting the progression of multiple sclerosis by blocking harmful B cells – FierceBiotech

Thursday, November 14th, 2019

The blood-brain barrier in healthy people is a powerful shield that protects neurons from harmful invaders. But in people with multiple sclerosis (MS), that shield malfunctions, allowing B cells from the immune system to pass into the brain and destroy healthy tissues.

Scientists at the University of Montreal Hospital Research Centre (CRCHUM) have identified a new target that they suggest could be exploited to slow down the flow of B cells into the brains of people with MS. They reported the discovery in the journal Science Translational Medicine.

B cells produce a substance called activated leukocyte cell adhesion molecule (ALCAM) that allows them to migrate into the brain via blood vessels, the researchers found. Blocking ALCAM in mouse models of MS reduced the flow of B cells into the brain and slowed the progression of the disease, they reported.

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

RELATED: How new gene discoveries could guide precision medicine in multiple sclerosis

B cells are a major culprit in progressive MS, the most severe form of the disease, and there are drugs on the market designed to deplete them, including Roches Ocrevus. Novartis is in phase 3 trials of Arzerra (ofatumumab), a drug that eliminates B cells by binding to the surface protein CD20. Arzerra is approved to treat chronic lymphocytic leukemia, but Novartis has been gunning for a bigger market opportunity. In September, it released new phase 3 data showing that Arzerra reduced MS relapse rates by more than 50% when compared to Sanofis Aubagio.

Meanwhile, several academic teams are looking to genetics as a path to personalized MS treatment strategies. In October, researchers at Johns Hopkins reported that newly discovered variants in the genes C1, CR1 and C1QA are associated with vision loss in progressive MS. They believe further research into these complement genes could lead to the development of new MS therapies.

Blocking ALCAM could also offer a promising strategy for thwarting B cells in MS, said University of Montreal Professor Alexandre Prat, Ph.D., in a statement. "The molecule ALCAM is expressed at higher levels on the B cells of people with multiple sclerosis, he said. By specifically targeting this molecule, we will now be able to explore other therapeutic avenues for the treatment of this disease."

See the original post here:
Halting the progression of multiple sclerosis by blocking harmful B cells - FierceBiotech

Read More...

Page 33«..1020..32333435..40..»


2025 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick